GLUE
Monte Rosa Therapeutics, Inc.
$18.81
-0.07
(-0.37%)
Mkt Cap
1.22B
Volume
856,967
52W Range
3.9-25.77
Sector
Healthcare
Beta
1.62
EPS (TTM)
-1.86
P/E Ratio
-33.72
Revenue (TTM)
42.95M
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 123.67M | 75.62M | 0 | 0 | 0 | 0 | 0 |
| Net Income | (38.63M) | (72.70M) | (135.35M) | (108.50M) | (73.96M) | (35.88M) | (8.02M) |
| EPS | -0.46 | -0.98 | -2.63 | -2.30 | -1.59 | -0.82 | -0.18 |
| Free Cash Flow | (27.50M) | 38.01M | (62.84M) | (105.38M) | (69.09M) | (26.44M) | (7.56M) |
| FCF / Share | -0.33 | 0.51 | -1.22 | -2.23 | -1.48 | -0.60 | -0.17 |
| Operating CF | (22.80M) | 42.00M | (43.80M) | (92.47M) | (59.36M) | (23.05M) | (6.17M) |
| Total Assets | 448.66M | 438.73M | 303.75M | 342.39M | 366.33M | 49.38M | 11.09M |
| Total Debt | 39.19M | 42.72M | 46.04M | 47.00M | 0 | 67.76M | 750,000 |
| Cash & Equiv | 129.88M | 224.25M | 128.10M | 54.91M | 346.07M | 41.70M | 6.00M |
| Book Value | 233.06M | 222.94M | 179.25M | 271.41M | 347.51M | (48.73M) | (12.15M) |
| Return on Equity | -0.17 | -0.33 | -0.76 | -0.40 | -0.21 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.21M | 2.78M | 12.77M | 23.19M | 84.93M | 60.65M | 9.22M | 4.70M | 1.06M | 0 | 0 | 0 |
| Net Income | (44.50M) | (46.13M) | (27.08M) | (12.29M) | 46.88M | 13.44M | (23.86M) | (30.31M) | (31.97M) | (33.25M) | (34.88M) | (35.18M) |
| EPS | -0.68 | -0.70 | -0.33 | -0.15 | 0.57 | 0.22 | -0.29 | -0.43 | -0.53 | -0.58 | -0.70 | -0.71 |
| Free Cash Flow | (39.24M) | (43.78M) | 99.78M | (36.41M) | (47.08M) | 128.74M | (21.39M) | (29.79M) | (39.55M) | 27.95M | (26.36M) | (31.77M) |
| FCF / Share | -0.60 | -0.67 | 1.21 | -0.44 | -0.57 | 2.10 | -0.26 | -0.42 | -0.66 | 0.49 | -0.53 | -0.64 |
| Operating CF | (37.37M) | (43.01M) | 100.43M | (34.72M) | (45.49M) | 128.92M | (20.99M) | (27.77M) | (38.16M) | 29.63M | (24.71M) | (25.32M) |
| Total Assets | 736.43M | 448.66M | 459.84M | 359.59M | 393.20M | 438.73M | 315.08M | 344.11M | 266.75M | 303.75M | 252.10M | 278.62M |
| Total Debt | 39.06M | 39.19M | 40.17M | 41.13M | 41.86M | 42.72M | 43.70M | 44.36M | 45.18M | 46.04M | 46.40M | 47.03M |
| Cash & Equiv | 159.86M | 129.88M | 208.34M | 69.43M | 78.53M | 224.25M | 125.58M | 108.85M | 99.75M | 128.10M | 59.05M | 47.03M |
| Book Value | 521.92M | 233.06M | 245.84M | 268.08M | 275.16M | 222.94M | 205.46M | 224.67M | 152.52M | 179.25M | 184.52M | 213.65M |
| Return on Equity | -0.09 | -0.20 | -0.11 | -0.05 | 0.17 | 0.06 | -0.12 | -0.13 | -0.21 | -0.19 | -0.19 | -0.16 |
GLUE News
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics (GLUE) Reports Q1 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Receives $32.80 Average PT from Analysts
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer